

## Patent Assignment Abstract of Title

**NOTE: Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.**

### Total Assignments: 2

**Patent #:** 6264922 **Issue Dt:** 07/24/2001 **Application #:** 08948216 **Filing Dt:** 10/09/1997

**Inventors:** RAY W. WOOD, LAN DECASTRO, H. WILLIAM BOSCH

**Title:** NEBULIZED AEROSOLS CONTAINING NANOPARTICULATE DISPERSIONS

### Assignment: 1

**Reel/Frame:** 010797/0486

**Recorded:** 05/05/2000

**Pages:** 15

**Conveyance:** ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

**Assignor:** NANOSYSTEMS, L.L.C.

**Exec Dt:** 10/01/1998

**Assignee:** ELAN CORPORATION, PLC

LINCOLN HOUSE, LINCOLN PLACE  
DUBLIN 2, IRELAND

**Correspondent:** FOLEY & LARDNER

MICHELE M. SCHAFER  
WASHINGTON HARBOUR  
3000 K STREET, N.W., SUITE 500  
WASHINGTON, D.C. 20007-8696

### Assignment: 2

**Reel/Frame:** 010797/0501

**Recorded:** 05/05/2000

**Pages:** 17

**Conveyance:** ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

**Assignor:** ELAN CORPORATION, PLC

**Exec Dt:** 10/01/1998

**Assignee:** ELAN PHARMA INTERNATIONAL LIMITED

WIL HOUSE, SHANNON BUSINESS PARK  
SHANNON, CO. CLARE, IRELAND

**Correspondent:** FOLEY & LARDNER

MICHELE M. SCHAFER  
3000 K STREET, N.W.  
SUITE 500  
WASHINGTON, DC 20007-8696

Search Results as of: 02/03/2004 10:51 AM

D14

Atty. Dkt. No. 029318/0440

FORM PTO-1595 (modified)

(Rev. 6-93)

REC

05-23-2000

U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office

HEET

5:500



101364077

To the Commissioner of Patents and Trademarks. Please record the attached original documents or copies thereof.

1. Name of conveying party(ies):

NanoSystems, L.L.C.



Additional conveying party(ies) NO

2. Name and address of receiving party(ies):

Elan Corporation, PLC  
Lincoln House, Lincoln Place  
Dublin 2, IRELAND

3. Nature of conveyance:

ASSIGNMENT

Execution Date: October 1, 1998

Additional name(s) & address(es) attached? NO

4. Application number(s) or patent number(s):

If this is being filed together with a new application, the execution date of the application is: N/A

A. Patent Application Number(s):

08/948,216

B. Patent Number(s):

Additional numbers attached? NO

5. Name and address of party to whom correspondence concerning document should be mailed:

Michele M. Schafer  
POLLEY & LARDNER  
Washington Harbour  
3000 E. Street, N.W., Suite 500  
P.O. Box 25696  
Washington, D.C. 20007-8696

6. Total number of applications/patents involved: 1

7. Total fee (37 C.F.R. § 3.41): \$40.00

☒ Check Enclosed

Charge to deposit account

8. Deposit account number: 19-0741

05/22/2000 JENNAZZ 0000072 00944216

DO NOT USE THIS SPACE

01 FE:501

40.00 00

9. Statement and signature:

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. The Commissioner is hereby authorized to charge any additional recordation fees which may be required in this matter to the above-identified deposit account.

Michele M. Schafer

Name of person signing

*Michele M. Schafer*

Signature

May 5, 2000

Date

Total number of pages including cover sheet, attachments, and document: 15



# ASSET PURCHASE AGREEMENT

by and between

NANOSYSTEMS L.L.C.,  
EASTMAN KODAK COMPANY

and

ELAN CORPORATION, PLC

Dated as of August 21, 1998

NY1228: 97443.11

PATENT

REEL: 010797 FRAME: 0487



## SCHEDULES TO DISCLOSURE STATEMENT

Schedule 1.1(a)	Equipment
Schedule 1.1(b)	NanoSystems Real Property
Schedule 1.1(c)	NanoSystems Intellectual Property
Schedule 3.8	Capitalization
Schedule 3.10	Absence of Change
Schedule 4.5	Consents
Schedule 4.6(a)	Intellectual Property Infringements
Schedule 4.6(b)	Intellectual Property Restrictions
Schedule 4.8(a)	Material Contracts
Schedule 4.8(b)	Contracts: Breaches/Events
Schedule 4.8(c)	Certain Contracts
Schedule 4.9	Manufacturing Rights
Schedule 4.10	Administrative Actions
Schedule 4.13(a)	Benefit Plans
Schedule 4.13(f)	Payments Resulting from Transactions
Schedule 4.14(b)	Environmental
Schedule 4.17(c)	Commitments Since 12/31/97
Schedule 4.17(g)	Severance Payment
Schedule 4.20	Undisclosed Liabilities
Schedule 4.21	Insurance
Schedule 4.22	Year 2000 Compliance
Schedule 5.2	Commitments Prior to Closing
Schedule 5.5(a)	Severance Plan
Schedule 5.5(b)	Kodak Employee
Schedule 6.1(c)	Consents


EXHIBIT A Warrant Agreement

*Schedule  
1.1(c)  
IP*

NY12528: 97443.11

-v-

REEL: 010797 FRAME: 0488



# SCHEDULE 1.1.e

Systems Intellectual Property Portfolio of Pending and Granted Patents August 20, 1998			
Title of Invention	Country	Patent/Appln. No.	Status
Aerosols Containing Bacteriostatic Nanoparticle Dispersions	U.S.	Patent No. 5,747,801	Granted
	Canada	Appln. No. 2,313,846	Pending
	Europe	Appln. No. 94804567.1	Pending
	Japan	Appln. No. E-323798	Pending
Aerosols Containing Nanoparticle Dispersions	U.S.	Patent No. 5,747,801	Granted
	Canada	Appln. No. 2,313,838	Pending
	Europe	Appln. No. 94804568.3	Pending
	Japan	Appln. No. E-323798	Pending
Nanocrystalline Formulations of Human Immunodeficiency Virus (HIV) Protease Inhibitors Using Cellulose Surface Stabilizers and Methods of Making Such Formulations	U.S.	Appln. No. 08/890,402	Pending
	PCT	PCT/US91/14097	Pending
Pharmaceutical Compositions Containing Polyalkylene Block Copolymers Which Gel at Physiological Temperature	U.S.	Patent No. 5,343,188	Granted
	U.S.	Patent No. 5,783,194	Granted
	Canada	Appln. No. 2,313,643	Pending
	Europe	Appln. No. 94807083.3	Pending
	Japan	Appln. No. E-323803	Pending
Nanoparticles Containing the R(-) Enantiomer of Ibuprofen	U.S.	Patent No. 5,712,919	Granted
Formulations of Oral Gastrointestinal Therapeutic Agents in Combination with Pharmaceutically Acceptable Clays	U.S.	Patent No. 5,385,106	Granted
Microencapsulation of Nanoparticulate Pharmaceutical Agents	U.S.	Patent No. 5,360,932	Granted
Isolation of Ultra Small Particles	U.S.	Patent No. 5,303,723	Granted
Nanoparticulate Diagnostic Mixed Carbonic Anhydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging	U.S.	Patent No. 5,643,332	Granted
	U.S.	Patent No. 5,472,683	Granted
	U.S.	Patent No. 5,375,749	Granted
	U.S.	Patent No. 5,322,679	Granted
	U.S.	Patent No. 5,466,433	Granted
Iodinated Acryloyl Esters	U.S.	Patent No. 5,318,187	Granted
	U.S.	Patent No. 5,318,187	Granted
Method of Grinding Pharmaceutical Substances	Argentina	Appln. No. 326,206	Pending
	Australia	Patent No. 660832	Granted
	Canada	Appln. No. 2,107,400	Pending
	Taiwan	Patent No. NT-45476	Granted
	Czech Republic	Appln. No. 93/2277	Pending
	Europe	Appln. No. 93302785.6	Pending
	Finland	Patent/Appln. No. 934320	Pending

# SCHEDULE 1.1.c

## NanoSystems Intellectual Property Portfolio of Pending and Granted Patents August 20, 1998

Title of Invention	Country	Patent/Appn. No.	Status
Method of Grinding Pharmaceutical Substances	Hungary	Patent No. 218022	Granted
	Japan	Appn. No. 282497/93	Pending
	South Korea	Appn. No. 22264/93	Pending
	Malaysia	Patent No. MY-109,218-A	Granted
	Mexico	Appn. No. 93-6443	Pending
	New Zealand	Patent No. 248813	Granted
	Norway	Appn. No. 93-03719	Pending
	Philippines	Appn. No. 83A7839	Pending
	Russia	Patent/Appn. No. 93/52890	Pending
	Slovak Republic	Appn. No. PV 1361/93	Pending
	Ukraine	Appn. No. 93/2406	Pending
	Venezuela	Appn. No. 146093	Pending
	U.S.	Patent No. 5,373,783	Granted
Redispersible Nanoparticulate Film Matrices With Protective Overcoat	Canada	Appn. No. 2,312,883	Pending
	Europe	Appn. No. 94P04612.7	Pending
	Japan	Appn. No. 8-323046	Pending
Isolated Arzoxane Compounds	U.S.	Patent No. 5,384,107	Granted
Method to Reduce Particle Size Growth During Lyophilization	U.S.	Patent No. 5,382,401	Granted
Isolated Benzoyl Acetate and Ketals for X-Ray Imaging	U.S.	Patent No. 5,330,739	Granted
Formulations of Compounds as Nanoparticulate Dispersions in Digestible Oils or Fatty Acids	U.S.	Patent No. 5,371,536	Granted
	U.S.	Patent No. 5,360,931	Granted
	Canada	Appn. No. 2,307,364	Pending
	Europe	Appn. No. 94P04332.5	Pending
	Japan	National Phase Appn. of PCT/US96/01433	Pending
Use of Non-Ionic Cloud Point Modifiers to Minimize Nanoparticle Aggregation During Sterilization	U.S.	Patent No. 5,344,702	Granted
The Use of Tylosin as a Nanoparticle Stabilizer and Dispersant	U.S.	Patent No. 5,429,324	Granted
	Argentina	Appn. No. 328,199	Pending
	Australia	Patent No. 663648	Granted
	Canada	Appn. No. 2,108,192	Pending
	Taiwan	Appn. No. 83188780	Pending
	Europe	Appn. No. 93283363.7	Pending
	Finland	Pat/Appn. No. 93/3183	Pending
	Hungary	Pat/Appn. No. P9303394	Pending
	Israel	Appn. No. 93/167874	Pending
	Japan	Appn. No. 280799/93	Pending
	South Korea	Appn. No. 22700/93	Pending

# SCHEDULE I.I.c

## NanoSystems Intellectual Property Portfolio of Pending and Granted Patents August 28, 1998

Title of Invention	Country	Patent/Appln. No.	Status
The Use of Tyleaspal as a Nanoparticle Stabilizer and Dispersant	Malaysia	Appln. No. PI 9302834	Granted
	New Zealand	Patent No. 248726	Granted
	Norway	Appln. No. P834424	Pending
	Philippines	Patent No. 25937	Granted
	Russia	Appln. No. 93634841.00	Pending
	Slovak Republic	Appln. No. PV 1424-93	Pending
	Ukraine	Appln. No. 41003742	Pending
	U.S.	Patent No. 5,266,478	Granted
	Argentina	Appln. No. 324,628	Pending
	Australia	Patent No. 662442	Granted
Iodinated Aryloxy Carbonamides	Canada	Appln. No. 2,167,387	Pending
	Taiwan	Patent No. NI-672317	Granted
	Hungary	Pat/Appln. No. P8303473	Hungary
	Israel	Appln. No. 93/107834	Granted
	Japan	Appln. No. 24091593	Pending
	South Korea	Appln. No. 93/21154	Pending
	Malaysia	Patent No. MY-169,203A	Granted
	New Zealand	Patent No. 248431	Granted
	Philippines	Patent No. 30136	Granted
	Ukraine	Appln. No. 83/468	Pending
	Venezuela	Patent No. 138493	Granted
	U.S.	Patent No. 5,431,393	Granted
	U.S.	Patent No. 5,318,767	Granted
	Europe	Appln. No. 92266132.4	Pending
	U.S.	Patent No. 5,352,459	Granted
X-Ray Contrast Compositions Useful in Medical Imaging	Argentina	Appln. No. 324,523	Pending
	Taiwan	Appln. No. 83109723	Pending
	Japan	Appln. No. 21647293	Pending
	South Korea	Appln. No. 93/23383	Pending
	Malaysia	Appln. No. PI 9302359	Pending
	Mexico	Appln. No. 937381	Pending
	New Zealand	Patent No. 230116	Granted
	Philippines	Appln. No. 47231	Pending
	Russia	Appln. No. 93/33883	Pending
	Slovak Republic	Appln. No. PV 1416/93	Pending
Use of Purified Surface Modifiers to Prevent Particle Aggregation During Sterilization	U.S.	Appln. No. 08/600,006	Pending
	FCT	FCT/US94/03318	Pending
Formulations of Nanoparticulate Naproxen Tablets	U.S.	Appln. No. 08/600,006	Pending
	FCT	FCT/US94/03318	Pending

**SCHEDULE 1.1.c**

<b>NanoSystems Intellectual Property Portfolio of Pending and Granted Patents August 20, 1998</b>			
<b>Title of Invention</b>	<b>Country</b>	<b>Patent/Appln. No.</b>	<b>Status</b>
Reduction of Intravenously Administered Nanoparticle Formulation Induced Adverse Physiological Reactions	U.S.	Appln. No. 08/696,754	Pending (Allowed)
	Canada	Based on PCT/US96/15300	Pending
	Europe	Based on PCT/US96/15300	Pending
	Japan	Based on PCT/US96/15300	Pending
Process of Preparing X-Ray Contrast Compositions Containing Nanoparticles	U.S.	Patent No. 5,343,133	Granted
Sulfated Graft-Block Copolymer Surfactants as Stabilizer Coatings for Nanoparticle Compositions	U.S.	5,387,143	Granted
	Argentina	Appln. No. 132,233	Pending
	Australia	Appln. No. 28248/93	Pending
	Canada	Appln. No. 2,183,503	Pending
	Taiwan	Appln. No. 8408107531	Pending
	Europe	Appln. No. 93913868.5	Pending
	Finland	Pat/Appln. No. 933234	Pending
	Israel	Patent/Appln. No. 93/114354	Pending
	Japan	Appln. No. 303703/94	Pending
	Malaysia	Appln. No. PI 9301774	Pending
	Norway	Appln. No. F 943435	Pending
	Philippines	Appln. No. 38809	Pending
	Venezuela	Appln. No. 93/1026	Pending
	U.S.	Appln. No. 08/491,539	Pending (Allowed)
Method of Grinding Pharmaceutical Substances	Argentina	Appln. No. 931,938	Pending
	Canada	Appln. No. 2,196,966	Pending
	Taiwan	Appln. No. 84164440	Pending
	Europe	Appln. No. 93919219.4	Pending
	Israel	Appln. No. 93/115833	Allowed
	Japan	Appln. No. 338132/93	Pending
	Malaysia	Appln. No. PI 9301374	Pending
	Philippines	Appln. No. 50573	Pending
	Venezuela	Appln. No. 0833-93	Pending
Nanoparticles Diagnostic Devices as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging	U.S.	Patent No. 5,366,364	Granted
Method of Preparing Stable Drug Nanoparticles	U.S.	Patent No. 5,334,270	Granted
Sulfated Non-Ionic Block Copolymer Surfactants as Stabilizer Coatings for Nanoparticle Compositions	U.S.	Patent No. 5,369,441	Granted
Iodinated Aromatic Propandiolamine	U.S.	Patent No. 5,284,610	Granted
	U.S.	Patent No. 5,338,464	Granted
Iodinated Aromatic Ketones	U.S.	Patent No. 5,488,133	Granted



# SCHEDULE 1.1.c

## NanoSystems Intellectual Property Portfolio of Pending and Granted Patents August 20, 1998

Title of Invention	Country	Patent/Appn. No.	Status
Oral Purpose Diagnostic/Therapeutic Agent Containing a Tri-Iodinated Benzoyl Group Stabilized in a Conjugate	U.S.	Patent No. 5,643,330	Granted
Improved Formulations of Oral Gastrointestinal Diagnostic X-Ray Contrast Agents and Oral Gastrointestinal Therapeutic Agents	U.S.	Patent No. 5,628,981	Granted
Nanoparticles in Iodipamide Derivatives for Use as X-Ray Contrast Agents	U.S.	Appn. No. 08/813,348	Pending
	U.S.	Patent No. 5,321,218	Granted
Nanoparticle Diagnostic Diagnostic X-Ray Contrast Agents for Blood Pool and Therapeutic System Imaging	U.S.	Patent No. 5,323,328	Granted
Formulation SALT Formulations Stabilized by Non-Ionic and Anionic Stabilizers	U.S.	Patent No. 5,393,637	Granted
Water Insoluble Non-Magnetic Manganese Particles as Magnetic Resonance Enhancement Agents	U.S.	Patent No. 5,401,492	Granted
Novel Formulations for Nanoparticle X- Ray Blood Pool Contrast Agents Using High Molecular Weight Non-Ionic Surfactants	U.S.	Patent No. 5,324,352	Granted
	U.S.	Patent No. 5,447,710	Granted
Use of Ionic Cloud Point Modifiers to Prevent Particle Aggregation During Sterilization	U.S.	Patent No. 5,398,263	Granted
Use of Charged Phospholipids to Reduce Particle Aggregation	U.S.	Patent No. 5,476,583	Granted
Process of Preparing Therapeutic Compositions Containing Nanoparticles	U.S.	Patent No. 5,310,118	Granted
Nanoparticle NSAID Formulations	U.S.	Patent No. 5,318,733	Granted
	Canada	Appn. No. 2,312,779	Pending
	Europe	Appn. No. 96803181.2 (to be completed in all EP designated countries)	Pending (Allowed)
	Japan	Appn. No. 8-324268	Pending
Microprecipitation of Nanoparticle Pharmaceutical Agents	U.S.	Patent No. 5,340,933	Granted
Microprecipitation of Nanoparticle Pharmaceutical Agents Using Surface Active Material Derived From Similar Pharmaceutical Agents	U.S.	Patent No. 5,716,642	Granted
Co-Microprecipitation of Nanoparticle Pharmaceutical Agents with Crystal Growth Modifiers	U.S.	Patent No. 5,665,331	Granted
Co-Microprecipitation of Nanoparticle Pharmaceutical Agents with Crystal Growth Modifiers	U.S.	Patent No. 5,662,883	Granted
Surface Modified Drug Nanoparticles	U.S.	Patent No. 5,143,684	Granted
	Argentina	Appn. No. 92/321681	Pending

# SCHEDULE 1.1.e

NanoSystems Intellectual Property Portfolio of Pending and Granted Patents August 26, 1998			
Title of Invention	Country	Patent/Appln. No.	Status
Surface Modified Drug Nanoparticles	Australia	Patent No. 634536	Granted
	Canada	Appln. No. 2859433	Pending
	Chile	Appln. No. 920774	Pending
	Columbia	Patent No. 34433	Granted
	Europe	Appln. No. 91288133.2 Publication No. 499299	Pending
	Finland	Pat/Appln. No. 930331	Pending
	Hungary	Pat/Appln. No. 92-236	Pending
	Ireland	Appln. No. 92-0217	Pending
	Israel	Patent/Appln. No. 100734	Granted
	Japan	Appln. No. 92/11228	Pending
	South Korea	Appln. No. 92/1077	Pending
	Malaysia	Patent No. MY-100134-A	Granted
	Mexico	Patent No. 170543	Granted
	New Zealand	Patent No. 341362	Granted
	Norway	Appln. No. 92-00134	Allowed
	Philippines	Patent No. 29089	Granted
	Russia	Pat. No. 208433	Granted
	Singapore	Appln. No. 960361-3	Pending
	Taiwan	Patent No. NI-071312	Granted
Surface Modified Anticancer Nanoparticles	U.S.	Patent No. 5,484,643	Granted
	U.S.	Patent No. 5,389,343	Granted
	Argentina	Appln. No. 93/025,320	Pending
	Australia	Patent No. 875432	Granted
	Canada	Appln. No. 2858343	Pending
	Czech Republic	Appln. No. PV 131693	Pending
	China	Appln. No. 93108050.9	Pending
	Europe	Appln. No. 93201803.1 Publication No. 577215	Pending
	Finland	Pat/Appln. No. 933040	Pending
	Hungary	Pat/Appln. No. 9301917	Pending
	Israel	Patent/Appln. No. 106198	Pending
	Japan	Appln. No. 93/131808	Pending
	South Korea	Appln. No. 93/12287	Pending
	Malaysia	Appln. No. PI 9301273	Pending (allowed)
	Mexico	Appln. No. 933930	Pending
	New Zealand	Patent No. 248042	Granted
	Norway	Appln. No. 93-2403	Pending
	Philippines	Patent No. 30104	Granted
	Russia	Appln. No. 93046236	Pending
	Singapore	Appln. No. 9603603-6	Pending
	Slovak Republic	Pat/Appln. No. PV 0681-93	Pending
	Taiwan	Patent No. NI-079294	Granted
	Ukraine	Appln. No. 93000037	Pending

Issued and Granted Patents  
August 20, 1998

Title of Invention	Country	Patent/Appn. No.	Status
Surface Modified Anticancer Nanoparticles	Venezuela	Pat/Appn. No. 6848-01	Pending
Surface Modified NSAID Nanoparticles	U.S.	Patent No. 5,352,160	Granted
	Australia	Patent No. 677783	Granted
	Austria	European Patent No. 644 755	National Registration of EP 644 755
	Belgium	European Patent No. 644 755	National Registration of EP 644 755
	Canada	Appn. No. 2118317	Pending
	Denmark	European Patent No. 644 755	National Registration of EP 644 755
	Europe	European Patent No. 644 755	Granted
	France	European Patent No. 644 755	National Registration of EP 644 755
	Germany	European Patent No. 644 755	National Registration of EP 644 755
	Greece	European Patent No. 644 755	National Registration of EP 644 755
	Hungary	Pat/Appn. No. 94-3543	Pending
	Ireland	European Patent No. 644 755 Irish Patent No. 1572603	Granted
	Italy	European Patent No. 644 755	National Registration of EP 644 755
	Japan	Appn. No. 94/301515	Pending
	Luxembourg	European Patent No. 644 755	National Registration of EP 644 755
	Monaco	European Patent No. 644 755	National Registration of EP 644 755
	Mexico	Appn. No. 93-3455	Pending
	Netherlands	European Patent No. 644 755	National Registration of EP 644 755
	Portugal	European Patent No. 644 755	National Registration of EP 644 755
	Spain	European Patent No. 644 755	National Registration of EP 644 755

**NanoSystems Intellectual Property Portfolio of  
Pending and Granted Patents  
August 20, 1998**

Title of Invention	Country	Patent/Appln. No.	Status
Modified NSAID Nanoparticles	Sweden	European Patent No. 644 733	National Registration of EP 644 733
	Switzerland	European Patent No. 644 733	Granted
	United Kingdom	European Patent No. 644 733	National Registration of EP 644 733
Controlled Adhesion Within the GI-Tract of Nanoparticles Stabilized by High Molecular Weight, Linear Poly(cylixic acid) Polymers	U.S.	Patent No. 5,380,378	Granted
Imaging X-Ray Contrast Agents	U.S.	Patent No. 5,371,730	Granted
Base & Surfactant for Nanocrystals	U.S.	Patent No. 5,423,938	Granted
Formulations of Oral Gastrointestinal Imaging X-Ray Contrast Agents in Emulsion with Pharmaceutically Compatible Clays	U.S.	Patent No. 5,444,448	Granted
Formulations of Naproxen with Hydroxypropyl Cellulose as a Dispersion Stabilizer	U.S.	Patent No. 5,391,458	Granted
Formulations of 5-Substituted-Amino- Acidolates Useful as X-Ray Imaging Agents for Medical Diagnostic Imaging	U.S.	Patent No. 5,370,156	Granted
Formulations of (Alkanoxy) Amino-2,4,6- Trisubstituted Esters	U.S.	Patent No. 5,403,916	Granted
Continuous Method of Grinding Pharmaceutical Substances	U.S.	Patent No. 5,718,388	Granted
	Argentina	Appln. No. 331,937	Pending
	Canada	Appln. No. 2,190,134	Pending
	Taiwan	Appln. No. 84103642	Pending
	Europe	Appln. No. 93919081.0	Pending
	Israel	Appln. No. 111831	Pending
	Japan	Appln. No. 93938317	Pending
	Malaysia	Appln. No. P1 9301373	Pending
	Philippines	Appln. No. 93/36374	Pending
	Venezuela	Appln. No. 8834-93	Pending
Alkoxyphenyl Esters as Novel X-Ray Imaging Agents	U.S.	Appln. No. 64/677,708	Pending
Novel 3-Amino-Trilodophenyl Esters as X- Ray Contrast Agents	U.S.	Patent No. 5,668,166	Granted September 16, 1997
Polyether Copolymers and a Process for Preparing Them	U.S.	Appln. No. 64/677,709	Pending
	Argentina	Appln. No. 331,133	Pending
	Canada	Appln. No. 2,207,389	Pending
	Taiwan	Appln. No. 8460162792	Pending
	Europe	Appln. No. 93904320.4	Pending
	Israel	Appln. No. 84/6112134	Pending

**SCHEDULE 1.1:**

**NanoSystems Intellectual Property Portfolio of  
Pending and Granted Patents  
August 28, 1998**

<b>Title of Invention</b>	<b>Country</b>	<b>Patent/Appn. No.</b>	<b>Status</b>
Polymer Copolymers and a Process for Making Them	Europe	National Phase of PCT/EP94/04261	Pending
	Japan	National Phase of PCT/JP94/04261	Pending
	Malaysia	Appn. No. PI 950052	Pending
	Mexico	Appn. No. 931133	Pending
	Philippines	Appn. No. 30830	Pending
	Great Britain	Patent No. 2283977	Granted
	Venezuela	Appn. No. 93/124	Pending
Rhombohedral Crystalline Form of Triamcinolone Acetonide, Compositions Incorporating the Rhombohedral Crystalline Form of Triamcinolone Acetonide, Methods of Making and Using Such Compositions, and Methods of Making Nanocrystalline Compositions of Tetragonal Crystalline Form of Triamcinolone Acetonide	U.S.	Appn. No. 08/941,281	Pending
Injectable Formulations of Naproxen	U.S.	Appn. No. Unknown (filed on August 13, 1998)	Pending



the Acquired Assets are subject, other than in the case of clauses (ii) and (iii) any conflict, breach, default, termination, cancellation, acceleration, loss, violation or Encumbrance which, individually or in the aggregate, would not have a Material Adverse Effect or materially impair or delay Seller's ability to perform its obligations hereunder.

**4.4 Binding Effect.** This Agreement constitutes a valid and legally binding obligation of Seller enforceable in accordance with its terms, subject to bankruptcy, insolvency, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors' rights and to general equity principles.

**4.5 Consents and Approvals.** Except as required by the H-S-R Act, no consent, approval, waiver or authorization is required to be obtained by Seller from, and no notice or filing is required to be given by Seller to or made by Seller with, any Federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by Seller of this Agreement other than those the failure of which to obtain, give or make would not have a Material Adverse Effect or materially impair or delay the ability of Seller to effect the Closing.

**4.6 Intellectual Property.** To the best Knowledge of Seller, Seller owns or has the right to use all of the Intellectual Property included in the Acquired Assets. The Intellectual Property included in the Acquired Assets constitutes all of the Intellectual Property necessary to conduct the Business as currently conducted. Schedule 1.1(e) contains a worldwide list of all patents, trade names, trademarks and service marks, and applications for the foregoing owned or possessed by the Seller and true and complete copies of all such materials have been made available to Buyer. Seller has taken all action reasonably necessary to establish and protect its interest in and to the NanoSystems Intellectual Property. To the Knowledge of Seller, (i) Seller's products do not infringe on or otherwise violate the Intellectual Property of any other Person, and (ii) no Person is challenging, infringing or otherwise violating the NanoSystems Intellectual Property. Except as set forth in the Contracts listed on Schedule 4.6(b), there is no limitation on Seller's ability or right to license any of the NanoSystems Intellectual

NY12322: 97443.11

-17-

**Property to any Person** All issued patents and registered trademarks and service marks owned by Seller are recorded on the public record solely in the name of Seller.

**4.7 Title to and Condition of Tangible Property.** Seller has good title to, or a valid and binding leasehold interest in, the tangible property included in the Acquired Assets, free and clear of all Encumbrances, except (i) liens for Taxes, assessments and other governmental charges (a) not yet due and payable or (b) being contested in good faith by appropriate proceedings and for which adequate reserves have been established, and (ii) Encumbrances which, individually or in the aggregate, would not have a Material Adverse Effect. Upon the consummation of the transactions contemplated hereby, assuming Buyer is a bona fide purchaser for value with no knowledge of an adverse claim, Buyer will acquire good title to the tangible property included in the Acquired Assets, free and clear of all Encumbrances, except for the exceptions in clauses (i) and (ii) of this Section 4.7. The tangible property included in the Acquired Assets is in all material respects in good working condition, ordinary wear and tear excepted.

**4.8 Contracts**

(a) Schedule 4.8(a) sets forth a list, as of the date hereof, of each Contract that is material to Seller. Each such Contract is a valid and binding agreement of Seller or its Affiliates and is in full force and effect.

(b) To the Knowledge of Seller, there has been no material breach or default under any Contract listed on Schedule 4.8(a) except for defaults that have been cured or waived and breaches and defaults which are not material. No event has occurred with respect to Seller which, with notice or lapse of time or both, would constitute a material breach, violation or default, or give rise to a right of termination, cancellation, foreclosure, imposition of a lien or penalty, prepayment or acceleration under any such Contract.

(c) Seller is not a party to any Contract in any of the following categories:

NY12328:97443 11

-18-

**ASSIGNMENT OF INTELLECTUAL PROPERTY OTHER THAN PATENT**

KNOW ALL PERSONS BY THESE PRESENTS that in connection with the Asset Purchase Agreement, dated as of August 21, 1998 (the "Agreement"), by and among Elan Corporation, plc, a public limited company organized under the laws of Ireland ("Buyer"), NanoSystems L.L.C., a limited liability company organized under the laws of the State of Delaware ("Seller"), and Eastman Kodak Company, a New Jersey corporation (capitalized terms not defined herein shall have the meaning ascribed to them in the Agreement), Seller, for good and valuable consideration, receipt of which is hereby acknowledged, hereby ASSIGNS to Buyer all of Seller's right, title and interest in and to all Intellectual Property included in the Acquired Assets (other than the rights to develop and commercialize a nanocrystal version of Paclitaxel) in accordance with the terms of the Agreement.

IN WITNESS WHEREOF, Seller has caused this instrument to be executed by its duly authorized officer on the 1st day of October, 1998.

NANOSYSTEMS L.L.C.

By: Particulate Prospects Corp.,  
Member

By: *Akram Sandhu*  
Name: Akram Sandhu  
Title: Vice President

NY12523-1998203

Received 04-22-98 11:05am  
RECORDED: 05/05/2000

From-

To-FOLEY AND BROWNE  
PATENT Page 05  
REEL: 010797 FRAME: 0500